Press release
Neurodegenerative Disorders Market Accelerates at 5.8% CAGR Fueled by Breakthroughs in Neurology Research
Neurodegenerative Disorders Market Accelerates at 5.8% CAGR Fueled by Breakthroughs in Neurology Research
Asia remains the fastest-growing regional market, propelled by heavy healthcare infrastructure investments, improved diagnostic capabilities, and an expanding elderly population. Meanwhile, North America leads in market share thanks to strong R&D ecosystems, early adoption of advanced therapeutics, and supportive regulatory frameworks.
Get the Detailed Industry Analysis (including the Table of Contents, List of Figures, and List of Tables) - from the Neurodegenerative Disorders Market Research Report: https://marketgenics.co/reports/neurodegenerative-disorders-market-59115
Rising Disease Burden and Aging Population Accelerate Market Expansion
Growth in the Neurodegenerative Disorders Market is primarily driven by the rapid rise of Alzheimer's disease, Parkinson's disease, ALS, Huntington's disease, and Multiple Sclerosis (MS). According to global demographic trends, the population aged 60+ is expected to double by 2050. This aging shift significantly increases the risk of neurological diseases, directly influencing the neurodegenerative disease market.
Pharmaceutical and biotechnology companies are responding by intensifying investments in disease-modifying and neuroprotective therapies. For example, Johnson & Johnson showcased critical progress at the AAIC 2025 conference involving tau-targeting research and advanced biomarker discovery. These developments emphasize the industry's focus on early detection and treatment, aligning with the evolving needs of patients and caregivers.
Alzheimer's Disease Dominates the Neurodegenerative Disorders Landscape
Within the Neurodegenerative Disorders Market, Alzheimer's disease holds the largest revenue share, contributing around 45% of the total market. High disease burden, accelerating prevalence among aging populations, and robust R&D pipelines have cemented its leadership position.
Roche's innovations highlight this trend. The company demonstrated remarkable results for its bispecific antibody Trontinemab (Brainshuttle), delivering significant amyloid plaque reduction with a favorable safety profile. Additionally, the launch of the Elecsys pTau181 plasma test-a blood-based diagnostic tool-represents a major advancement in early, non-invasive Alzheimer's detection. Together, these innovations reinforce the company's strong foothold in the neurodegenerative diseases therapeutics market.
Advances in Early Diagnostics Strengthen Market Growth
Early diagnosis is a pivotal factor accelerating the expansion of the Neurodegenerative Disorders Market. The availability of advanced AI-powered tools, blood-based biomarkers, and precision imaging technologies is creating new possibilities for early intervention.
A notable example is IXICO plc's support for Fujirebio Diagnostics in securing FDA approval for a blood-based Alzheimer's biomarker test in 2025. This innovation enhances early disease detection and widens accessibility, enabling patients to receive treatment before significant cognitive decline begins.
Growing awareness campaigns across major regions are further encouraging timely diagnosis, improving patient outcomes, and enhancing overall market growth.
To know more about the Neurodegenerative Disorders Market - Download our Sample Report: https://marketgenics.co/download-report-sample/neurodegenerative-disorders-market-59115
Complex Biology and Clinical Barriers Challenge Therapeutic Development
Despite strong momentum, the neurodegenerative disease market faces several significant challenges. Neurodegenerative disorders involve multifaceted biological mechanisms, where the blood-brain barrier (BBB) restricts drug delivery and complicates therapeutic effectiveness. Additionally, patient heterogeneity-including genetic factors, disease progression variability, and biomarker diversity-reduces the consistency of clinical outcomes.
Long-duration, high-cost clinical trials intensify these challenges, increasing R&D risks and slowing market entry for new therapies. Translational discrepancies between animal models and human biology also lead to frequent trial failures, limiting advancements in the neurodegenerative diseases therapeutics market.
Gene and Cell Therapies Unlock Transformative Opportunities
Despite challenges, one of the most transformative growth opportunities in the Neurodegenerative Disorders Market lies in gene and cell therapy innovation. Breakthroughs in CRISPR gene editing, AAV vector technologies, and regenerative stem cell interventions are reshaping therapeutic possibilities.
A major milestone is UniQure's AMT-130 gene therapy for Huntington's disease, which demonstrated a 75% reduction in progression in Phase I/II trials. Backed by FDA Fast Track, Breakthrough, RMAT, and Orphan Drug designations, this therapy exemplifies how gene-silencing technologies could revolutionize the neurodegenerative diseases therapeutics market in the coming decade.
These advancements not only open the door to potentially curative treatments but also attract substantial investments and partnerships across the global biotech ecosystem.
Buy Now: https://marketgenics.co/buy/neurodegenerative-disorders-market-59115
AI and Digital Health Integration Accelerates Innovation
One of the most influential trends reshaping the Neurodegenerative Disorders Market is the integration of AI-driven drug discovery and digital health solutions. Artificial intelligence has dramatically enhanced target discovery, biomarker validation, and trial optimization, collectively reducing the time and cost associated with neurodegenerative drug development.
Companies like Altoida Inc. are pioneering AI-powered cognitive testing through smartphone applications. Their 2025 initiative, involving top global experts in AI, neuroscience, and Alzheimer's research, aims to accelerate the development of an AI-based brain health platform capable of early disease detection. This technological convergence is bridging the gap between research and clinical care, improving diagnostic accuracy and facilitating better patient outcomes.
North America Leads Global Adoption and Innovation
North America dominates the Neurodegenerative Disorders Market, driven by:
A rapidly aging population
Strong healthcare infrastructure
Innovative diagnostic platforms
Active participation from major pharmaceutical giants like Biogen, Eli Lilly, Roche, and Novartis
Government and private funding remain strong, exemplified by the joint $5.4 million investment by CQDM and Brain Canada Foundation to stimulate neuroscience innovation. Favorable FDA pathways for gene and cell therapies further boost the region's leadership in the neurodegenerative disease market.
Get a preview of our Neurodegenerative Disorders Market Playbook - your guide to GTM strategy, competitive intelligence, supplier dynamics, and Consumer Behavior Analysis: https://marketgenics.co/playbook/neurodegenerative-disorders-market-59115
Competitive Landscape: Leading Players Accelerate R&D
The market is moderately fragmented, with the top five players capturing around 28-30% of global share. Major participants include:
Biogen Inc.
Eli Lilly and Company
Roche Holding AG
Novartis AG
AstraZeneca plc
Pfizer Inc.
Sanofi S.A.
Johnson & Johnson
Teva Pharmaceuticals
These companies continue to strengthen their pipelines through collaborations, clinical trial expansion, and strategic partnerships with CROs, CDMOs, and academic institutions.
Two significant developments in 2025 include:
Klotho Neurosciences receiving FDA Orphan Drug Designation for KLTO-202 for ALS
Bexorg partnering with Biohaven to integrate AI-powered whole-brain discovery into CNS drug development
Such partnerships enhance innovation speed, diversify therapeutic platforms, and boost competitiveness across the neurodegenerative diseases therapeutics market.
Future Outlook: A USD 30 Billion Opportunity by 2035
The Neurodegenerative Disorders Market is expected to create nearly USD 30 billion in new growth opportunities by 2035. Key catalysts include:
Rising adoption of precision medicine
Surge in gene and cell therapy approvals
Expansion of AI-enabled diagnostics
Improving reimbursement for neurological treatments
Growing investments in rare and orphan neurological diseases
North America and Asia Pacific will be the most influential regions, driven by innovation leadership and rapid healthcare modernization, respectively.
Contact:
Mr. Debashish Roy
MarketGenics India Pvt. Ltd.
800 N King Street, Suite 304 #4208, Wilmington, DE 19801, United States
USA: +1 (302) 303-2617
Email: sales@marketgenics.co
Website: https://marketgenics.co
About Us
MarketGenics is a global market research and management consulting company empowering decision makers across healthcare, technology, and policy domains. Our mission is to deliver granular market intelligence combined with strategic foresight to accelerate sustainable growth.
We support clients across strategy development, product innovation, healthcare infrastructure, and digital transformation.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Neurodegenerative Disorders Market Accelerates at 5.8% CAGR Fueled by Breakthroughs in Neurology Research here
News-ID: 4270828 • Views: …
More Releases from MarketGenics India Pvt. Ltd.
APAC Deepfake Detection Market Accelerates as Governments Tighten Digital Trust …
A Market Transforming How the World Verifies Reality
The global deepfake detection technology market, valued at USD 0.6 billion in 2025, is positioned to accelerate at a powerful 37.2% CAGR, reaching USD 15.1 billion by 2035.
This growth is driven by one undeniable truth:
Synthetic media is reshaping the threat landscape faster than humans can recognize it.
Deepfake detection technologies now determine:
How newsrooms verify breaking content
How financial institutions prevent identity-spoofing
How governments protect election integrity
How…
Travel & Expense Management Software Market Signals a Digital Pivot | AI, Cloud …
The Travel and Expense Management (TEM) Market Crossroads | A Sector Accelerating, Repricing Efficiency, and Redrawing the Corporate Spend Map
(Is TEM a Back-Office Tool-or the Operating System of the Next Enterprise Economy?)
For years, the travel and expense management software market lived in the administrative shadows-handed off to finance teams, constrained by spreadsheets, and dismissed as a routine cost-control tool. But the numbers now tell a radically different story.
In 2025, the…
Oilfield Equipment Market hits USD 116.2B in 2025 and grows to USD 156.5B by 203 …
Oilfield Equipment Market | The $156.5B Hardware Backbone of the Global Energy System
Every headline loves clean energy. Yet the global energy mix still demands a brutal truth: oil and gas remain the world's primary supply of heat, mobility, and petrochemicals - and the machines that drill, lift, complete, and produce hydrocarbons continue to define industrial capability.
That's why the Oilfield Equipment Market remains a strategic industry - not a relic.
In 2025,…
Machine Tools Market 2025-2035 | USD 109.9B Growth, CNC & Automation Trends
Machine Tools Market | The $109.9B Intelligence Engine of Global Manufacturing
Factories don't work without machine tools. They shape, cut, drill, grind, and define the physical world around us. Yet most end-products - cars, aircraft parts, electronics housings, surgical devices - never reveal the precision machinery behind them.
The Machine Tools Market is the invisible infrastructure that turns digital models into physical reality.
In 2025, the global Machine Tools Market stands at USD…
More Releases for Neurodegenerative
Growing Prevalence Of Neurodegenerative Disorders Fuels Neurodegenerative Disord …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
Neurodegenerative Disorder Therapeutics Market Size Growth Forecast: What to Expect by 2025?
In recent times, the market size for therapeutics for neurodegenerative disorders has seen robust growth. The growth is expected to rise from $18.53 billion in 2024 to $20.04 billion in 2025, maintaining a compound annual growth rate…
Growing Prevalence Of Neurodegenerative Disorders Fuels Neurodegenerative Disord …
"The Neurodegenerative Disorder Therapeutics Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Current Neurodegenerative Disorder Therapeutics Market Size and Its Estimated Growth Rate?
The neurodegenerative disorder therapeutics market has shown strong growth, expected to increase from $18.53 billion in 2024 to $20.04 billion…
Growing Prevalence Of Neurodegenerative Disorders Fuels Neurodegenerative Disord …
How Is the Neurodegenerative Disorder Therapeutics Market Projected to Grow, and What Is Its Market Size?
Seen significant expansion in recent years, the market size for neurodegenerative disorder therapeutics is predicted to climb from $18.53 billion in 2024 to $20.04 billion in 2025, maintaining a compound annual growth rate (CAGR) of 8.1%. The prior growth phase can be credited to factors such as an aging society, an upsurge in neurodegenerative disorder…
Growing Prevalence Of Neurodegenerative Disorders Fuels Neurodegenerative Disord …
How Is the Neurodegenerative Disorder Therapeutics Market Projected to Grow, and What Is Its Market Size?
Seen significant expansion in recent years, the market size for neurodegenerative disorder therapeutics is predicted to climb from $18.53 billion in 2024 to $20.04 billion in 2025, maintaining a compound annual growth rate (CAGR) of 8.1%. The prior growth phase can be credited to factors such as an aging society, an upsurge in neurodegenerative disorder…
Growing Prevalence Of Neurodegenerative Disorders Fuels Neurodegenerative Disord …
How Is the Neurodegenerative Disorder Therapeutics Market Projected to Grow, and What Is Its Market Size?
Seen significant expansion in recent years, the market size for neurodegenerative disorder therapeutics is predicted to climb from $18.53 billion in 2024 to $20.04 billion in 2025, maintaining a compound annual growth rate (CAGR) of 8.1%. The prior growth phase can be credited to factors such as an aging society, an upsurge in neurodegenerative disorder…
Novel Antibodies in Neurodegenerative Disease Treatment
Neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease, represent some of the most challenging medical conditions due to their progressive nature and lack of effective treatments. Novel antibodies are emerging as promising therapeutic agents, offering targeted and innovative approaches to slow disease progression and improve patient outcomes. This article explores the role of novel antibodies in the treatment of neurodegenerative diseases, highlighting their mechanisms of action and therapeutic potential.
Download…
